Drug Trial Radar · NCT06596005
Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Sep 18, 2024
Primary completion
Sep 3, 2025
Study completion Sep 9, 2025
Sponsor
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Taizhou Hospital; Wenzhou Central Hospital; Sir Run Run Shaw Hospital; The Second Affiliated Hospital of Jiaxing University; Hangzhou PhecdaMed Co., Ltd.; Huzhou Central Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo parallel-controlled Phase II clinical trial to evaluate the efficacy and safety of TJ0113 capsule in patients with early-stage Parkinson's disease
Conditions
- Parkinson Disease
Interventions
TJ0113 200mgDrug
200 mg Capsule, Once Daily
TJ0113 400mgDrug
400 mg Capsule, Once Daily
PlaceboDrug
Capsule, Once Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes From Baseline in Scores of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) in Subjects After 12 Weeks of Treatment.Evaluation Time Point: ≥ 12 Hours From the Most Recent Dose of Anti-PD Drug.Time frame: After 12 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.